« Why Amgen betting on the River with BioVex? | Main | It's Not 'Me-Too', It's Really a Failed Race for First-in-Class »



TrackBack URL for this entry:

Listed below are links to weblogs that reference Will This be "New Normal" Business Model for Biotech?:


Feed You can follow this conversation by subscribing to the comment feed for this post.

David E Leahy

I am sure this also works for earlier stage projects sitting on the shelf in Big Pharma as a "data, information and materials" package that someone else could acquire and develop. The owner could get first rights at licensing back in downstream and retain an equity stake in the financing vehicle for the project.


I think the mechanism that you suggest for incremental development with "shelved" projects is viable an dit might be applied to some of the academic settign that are trying to become more translational too.


Interesting post.

With the current big pharma focus on getting late stage compounds across the finish line and onto the market, I suspect we will see even more early stage deals coming in a couple of years as big pharma starts refilling the early pipeline.

Is there an opportunity for small development companies to be formed to take 'shelved', early stage products off big pharma, develop them and sell them back? Roche have used this this approach in the past with the formation of Basilea, and Novartis did it with Speedel.

The comments to this entry are closed.

My Photo
Blog powered by Typepad
Member since 12/2009
Bookmark and Share

July 2014

Sun Mon Tue Wed Thu Fri Sat
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

Innovate on Purpose

In the Pipeline

Life Sci VC

visited 6 states (46.1%)
Create your own visited map of Canada